L., Roma-Mateo, C., Perez-Machado, G., Peiro-Chova, L
A MONOCLONAL ANTISARSCOV2 IGG ADMINISTERED BY INTRAVENOUS OR NEBULIZATION ROUTE REDUCES VIRAL LOAD IN UPPER AND LOWER RESPIRATORY TRACT Benot Delache1 *, Ccile Hrate1*, Paule Hermet2, Andres Mnnik2, Quentin Sconosciuti1, Francis Relouzat1, Asma Berriche1, Thibaut Nanninck1, Nathalie DeureuddreBosquet1, Roger Le Grand1 and Mart Ustav Jr2 aUniversit ParisSaclay, Inserm, CEA, Center for Immunology of Viral, Autoimmune, Hematological and Bacterial diseases (IMVAHB/IDMIT), FontenayauxRoses & Le KremlinBictre, Paris, France bIcosagen Cell Factory O, Tartu, Estonia, Summary: Icosagen developed an antiSarsCOV2 neutralising monoclonal antibody (VH16VL104) effective in vitro against multiple variants of the virus including the Delta and Omicron variants of concern (VOC)
Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells
Y., Embry, M
The issue is a trending topic on all platforms, the #ozempic hashtag has well over a billion views on TikTok, where GLP-1 influencers share their experiences with the audience
